Association of inflammatory blood markers and pathological complete response in HER2-positive breast cancer: a retrospective single-center cohort study

作者：Xiaobin Chen, Qindong Cai, Lin Deng, Minyan Chen, Xu Min, Lili Chen, Yuxiang Lin, Li Yan, Yali Wang, Hanxi Chen, Shunyi Liu, Jinqiao Wu, Xin Tong, Fangmeng Fu, Chuan Wang · 发表于：Frontiers in Immunology · 年份：2024 · DOI：10.3389/fimmu.2024.1465862 · 被引用次数：9 · 研究领域：Inflammatory Biomarkers in Disease Prognosis、Immune cells in cancer、Cancer, Lipids, and Metabolism

Introduction The association between inflammatory blood markers (IBMs) (monocyte-to-lymphocyte ratio [MLR], neutrophil-to-lymphocyte ratio [NLR], and platelet-to-lymphocyte ratio [PLR]) and breast cancer has been extensively studied. However, the predictive role of IBMs in the neoadjuvant response of human epidermal growth factor receptor 2 (HER2)-positive breast cancer remains unclear. Methods This study included 744 patients with HER2 positive breast cancer treated with neoadjuvant therapy. Baseline MLR, NLR, and PLR data were collected to investigate the association between IBMs and pathological complete response (pCR). Results MLR, NLR, and PLR were not associated with neoadjuvant response in the overall population before and after matching. Subgroup analysis stratified by neoadjuvant therapy suggested that these IBMs play a diverse predictive role in response to chemotherapy alone and chemotherapy plus anti-HER2 therapy. A high MLR and NLR, but not PLR, were associated with lower pCR rates in HER2-targeted therapy (MLR: OR=0.67, P =0.023; NLR: OR=0.665, P =0.02; PLR: OR=0.801, P =0.203). Among the anti-HER2 treatment population, patients with a high MLRs (pCR rate, 40.2%) could be divided into MLR high /NLR high (pCR rate, 36.3%) and MLR high /NLR low (pCR rate, 48.9%) groups when the NLR was considered. The pCR rates of the MLR high /NLR low and low-MLR groups were similar (pCR rate, 47.6%). A comparable stratification effect was observed in patients with high NLR. Conc...